PSYCHPSYCHPSYCH
  • REPORT
  • CONFERENCE
  • NEWS AND INSIGHTS
  • NEWSLETTER
  • REPORT
  • CONFERENCE
  • NEWS AND INSIGHTS
  • NEWSLETTER
  • UNLOCKING THE COMMERCIAL POTENTIAL OF PSYCHEDELICS
    DOWNLOAD THE REPORT
    SUBSCRIBE TO NEWSLETTER

OUR MISSION

The global psychedelics industry is expected to be worth over US$100 billion with the potential to save $1 trillion on lost productivity, disrupting the way we approach healthcare. As attitudes towards psychedelics shift dramatically, we are witnessing an international rise in clinical trials, academic research and commercial investment. The use of psychedelics as medicine is set to open up a new industry at pace. We help investors, operators and regulators navigate the many opportunities through data, intelligence and networking.

OFFERING

We demystify the legislative and regulatory environment surrounding a variety of psychedelics, helping our clients to navigate the changing landscape of each region.

We provide market forecasts and estimates for potential savings to society/economy which are likely to result from psychedelic therapies over the next decade.

We identify and analyse emerging trends for individual psychedelic therapies and monitor innovation and developments in this exciting, burgeoning industry.

THE PSYCHEDELICS AS MEDICINE REPORT: SECOND EDITION

DISRUPTING MODERN HEALTHCARE

Medical psychedelics are experiencing a renaissance, pushing forward the frontiers of healthcare innovation. The Psychedelics as Medicine Report: Second Edition provides unparalleled consumer insights and market intelligence from experts and industry leaders, helping to guide investors, operators and regulators through this transient phase. Download your free copy now.


The Psychedelics as Medicine Report: Second Edition examines:

  • Proprietary consumer insights on attitudes, uses and behaviours
  • Deep dives into the most transformative compounds and companies
  • Key regulations, transformative trends and commercial opportunities

HIGHLIGHTS AND INSIGHTS

PSYCH: What are the next steps
for investors?

PSYCH: What Lies Ahead?
The Future of Therapy

PSYCH: Psychedelics for
Substance Use

PSYCH: Lessons Learned from 50 Years of Psychedelic Activism

NEWS & INSIGHT

Professor David Nutt: The Therapeutic Use of Psychedelics

During The PSYCH Symposium in November 2020, Professor David Nutt, chairman of Awakn Life Sciences, founder of Drug Science and the director of neuropsychopharmacology at Imperial College London, delivered a virtual keynote speech on the impact of psychedelic medicines across history and culture before covering the complex and unbridled potential they hold in the treatmentContinue reading

Read more

Gwella and the Untapped Opportunity In Functional Mushrooms

A new company straddling both the functional health and psychedelic space with a consumer/retail first approach. Backed by a leading team of scientists, doctors, investors and experts across the wellness space, the company has full service creative, digital marketing, and e-commerce expertise, which is supported by a board with extensive knowledge of developing, marketing andContinue reading

Read more

St. Vincent and the Grenadines Launch Psychedelics Initiative

Exclusive: Saint Vincent and the Grenadines announces initiative to permit psychedelic treatment and research  The Caribbean nation of Saint Vincent and the Grenadines has launched an initiative to permit and support psychedelic research and wellness. The initiative will begin as a Medicinal Wellness Feasibility Study, which is expected to last 24 to 30 months, andContinue reading

Read more

THE PSYCHEDELICS NEWSLETTER

Expert analysis and intelligence, straight to your inbox. Join industry insiders and subscribe for exclusive news, data and insights from across the psychedelics industry.

ISSUES

Issue 13

The psychedelic compound known as DMT will be used in a trial to treat depression for the first time in the United Kingdom while MDMA has been proven to help people suffering from alcohol addiction.

Enjoy Issue 13 of The Psychedelics Newsletter, here.

 

Issue 14

PSYCH hits 25,000 subscribers to become industry’s fastest-growing newsletter while a number of major announcements on the advancement of research into psychedelic medicines have been made.

Enjoy Issue 14 of The Psychedelics Newsletter, here.

 

Follow us on Twitter

PSYCH@psych_pp·

This looks like a good event this week from @kcsastrategic 👍

Twitter 1353814354261663744
PSYCH@psych_pp·

"Despite psilocybin being a Schedule I substance in the US & a Class A substance in the UK — the most restrictive categories — the researchers found that most participants considered psilocybin to be relatively safe compared to the other substances."
https://journals.sagepub.com/doi/abs/10.1177/0269881120936508

Twitter 1353749630929031170
PSYCH@psych_pp·

Very useful tool that separates the genuine IP value from the hype when it comes to drug development in psychedelics.

Great work @MichaelHaichin @PsilocybinAlpha 👍🍄

https://psilocybinalpha.com/data/psychedelic-drug-development-tracker

Twitter 1353645600953274368
PSYCH@psych_pp·

During The PSYCH Symposium in November, @ProfDavidNutt, one of the leading figures operating in the psychedelics sector, delivered a keynote speech & presented an overview of the impact and potential of psychedelic medicines for society.

Highlights here:
https://psych.prohibitionpartners.com/david-nutt-the-therapeutic-use-of-psychedelics/

Twitter 1352289754189099010
PSYCH@psych_pp·

📩PSYCH hits 25,000 subscribers to become industry's fastest growing newsletter
💊Awakn to conduct phase II study on MDMA for alcohol use disorder
🧠David Nutt on the therapeutic use of psychedelics

All this & more in The Psychedelics Newsletter, Issue 14 https://psych.prohibitionpartners.com/psych_fortnightly/issue-14/

Twitter 1351975992995295233
PSYCH@psych_pp·

A retired Fireman has said that using psychedelic medicines helped to save his life amid a personal mental health crisis.
https://toronto.citynews.ca/2021/01/21/retired-firefighter-claims-a-psychedelic-drug-saved-his-life/

Twitter 1352979516474449921
Load More...
+44 (0) 203 928 2814
20-22 Wenlock Road, London, N1 7GU, United Kingdom

 

©2021 PP Intelligence LTD. (t/a PSYCH)

Privacy Policy